Matthew Shields Sells 6,206 Shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA) Stock

Teva Pharmaceutical Industries Limited (NYSE:TEVA) EVP Matthew Shields sold 6,206 shares of the stock in a transaction on Tuesday, June 3rd. The shares were sold at an average price of $17.02, for a total value of $105,626.12. Following the sale, the executive vice president now owns 9,989 shares in the company, valued at $170,012.78. The trade was a 38.32% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this link.

Teva Pharmaceutical Industries Stock Performance

Shares of NYSE:TEVA opened at $17.76 on Friday. The firm’s 50 day simple moving average is $15.72 and its 200-day simple moving average is $17.39. The company has a debt-to-equity ratio of 2.97, a quick ratio of 0.75 and a current ratio of 0.98. Teva Pharmaceutical Industries Limited has a one year low of $12.47 and a one year high of $22.80. The firm has a market cap of $20.37 billion, a PE ratio of -12.25, a price-to-earnings-growth ratio of 1.44 and a beta of 0.60.

Teva Pharmaceutical Industries (NYSE:TEVA) last posted its quarterly earnings results on Wednesday, May 7th. The company reported $0.52 earnings per share for the quarter, beating the consensus estimate of $0.47 by $0.05. The firm had revenue of $3.89 billion during the quarter, compared to the consensus estimate of $3.99 billion. Teva Pharmaceutical Industries had a negative net margin of 9.91% and a positive return on equity of 42.46%. The company’s revenue was up 1.9% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.48 earnings per share. As a group, equities analysts predict that Teva Pharmaceutical Industries Limited will post 2.5 EPS for the current year.

Analyst Ratings Changes

Several brokerages have recently weighed in on TEVA. JPMorgan Chase & Co. raised shares of Teva Pharmaceutical Industries from a “neutral” rating to an “overweight” rating and increased their target price for the company from $21.00 to $23.00 in a research note on Monday, May 12th. Wall Street Zen raised shares of Teva Pharmaceutical Industries from a “hold” rating to a “buy” rating in a research note on Thursday, May 22nd. Hsbc Global Res raised shares of Teva Pharmaceutical Industries to a “strong-buy” rating in a research report on Monday, April 28th. The Goldman Sachs Group assumed coverage on shares of Teva Pharmaceutical Industries in a research report on Friday. They issued a “buy” rating and a $24.00 price objective on the stock. Finally, Bank of America increased their price target on Teva Pharmaceutical Industries from $20.00 to $22.00 and gave the stock a “buy” rating in a report on Thursday, May 8th. Nine investment analysts have rated the stock with a buy rating and two have given a strong buy rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Buy” and an average target price of $24.44.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of the company. Barclays PLC increased its stake in shares of Teva Pharmaceutical Industries by 31.7% during the third quarter. Barclays PLC now owns 427,595 shares of the company’s stock valued at $7,705,000 after buying an additional 102,848 shares during the period. Yousif Capital Management LLC increased its position in Teva Pharmaceutical Industries by 3.5% during the 4th quarter. Yousif Capital Management LLC now owns 54,953 shares of the company’s stock valued at $1,211,000 after purchasing an additional 1,872 shares during the period. Migdal Insurance & Financial Holdings Ltd. increased its position in Teva Pharmaceutical Industries by 2.2% during the 4th quarter. Migdal Insurance & Financial Holdings Ltd. now owns 26,035,422 shares of the company’s stock valued at $573,822,000 after purchasing an additional 569,412 shares during the period. Sumitomo Mitsui Trust Group Inc. increased its position in Teva Pharmaceutical Industries by 20.7% during the 4th quarter. Sumitomo Mitsui Trust Group Inc. now owns 2,369,302 shares of the company’s stock valued at $52,219,000 after purchasing an additional 405,741 shares during the period. Finally, Ameliora Wealth Management Ltd. purchased a new position in Teva Pharmaceutical Industries during the 4th quarter valued at about $66,000. 54.05% of the stock is currently owned by hedge funds and other institutional investors.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.